Teresa Amaral, Subject Editor of ESMO Clinical Practice Guidelines for Melanoma & Other Skin Cancers, shared a post on LinkedIn:
“From Science to Access: Where are we in cancer care in 2025?” – This was the starting point of the discussion last week at the European Parliament hosted by MEP Romana Jerković, and organized by EFPIA – European Federation of Pharmaceutical Industries and Associations, where the key findings from the IHE Comparator Report on Cancer in Europe 2025 were presented.
I had the privilege to represent ESMO – European Society for Medical Oncology and to share some insights on the road blocks to equitable access to scientific innovation for patients with cancer in Europe.
Science is working, and, as said during the meeting, science doesn’t seem to be the limiting factor. The Beating Cancer Plan (BCP) is an excellent foundation, but, similar to building a solid house, you don’t stop at the foundation – you need the floor, the walls, the ceilings, the furniture … So we need to continue working upstream (or downstream, depending on how you see it), and make sure that this project is not ending with of the BCP. The BCP is a once in lifetime opportunity that needs to be grasped and delivered in full, if it is to be the expected game changer.
Several practical aspects and current road blocks were discussed, including the challenges associated with the implementation of the current IVDR legislation. Full document on ESMO’s position here.
Thanks to all the speakers (Thomas Hofmarcher Mario Šekerija Gijs Geleijnse, Elisabetta Zanon Barbara Peric, GILLES VASSAL and Francisco Lozano), the moderator (Sarah-Taïssir Bencharif, MD), and all attendees for making this a great and valuable event.
Watch the space for future updates.
Thanks Isha Jerath and Boglárka Pataki for the pics.”
More posts featuring Teresa Amaral on OncoDaily.